Hilden, Germany, and Germantown, Maryland, February 26, 2020 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has shipped its newly developed QIAstat-Dx Respiratory Panel 2019-nCoV test kit to four hospitals in China for evaluation. The new kit detects the novel coronavirus SARS-CoV-2 and adds rapid Sample to Insight syndromic testing to QIAGEN’s... Read more
Hilden, Germany, and Germantown, Maryland, February 20, 2020 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Nigeria, the country with the largest population in Africa and one of the world’s 30 high-disease burden countries for tuberculosis (TB), has published guidelines recommending QuantiFERON®-TB Gold Plus (QFT®-Plus) in screening for latent TB infection (LTBI)... Read more
Delivers on Q4 2019 net sales outlook, exceeds on adjusted EPS Net sales of $413.5 million (+3% actual, +4% CER, vs. ~+3% CER outlook) Diluted EPS $0.19; adjusted EPS $0.48 ($0.48 CER, +20% CER vs. ~$0.45-0.46 CER outlook) Adjusted operating income margin rises to 33.5% of sales vs. 29.6% in Q4 2018 Achieves FY 2019... Read more
Germantown, Maryland, and Hilden, Germany, February 3, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marking and launch of its therascreen® PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a PIK3CA mutation. Last year the therascreen PIK3CA test was approved by the FDA... Read more
Redwood City, California, and Hilden, Germany, January 15, 2020 – QIAGEN today announced the launch of QCI Precision Insights in Europe, with the inclusion of the European Society for Medical Oncology (ESMO) guidelines and European Medicines Agency (EMA) approved oncology drugs catalogue. QCI Precision Insights is a clinical interpretation service provided by a team of molecular... Read more
Hilden, Germany and Germantown, Maryland, January 13, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration to develop tissue-based companion diagnostics for Amgen’s investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation. The agreement focuses initially on companion diagnostics for non-small cell... Read more
Hilden, Germany, and Germantown, Maryland, January 9, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the 2,500th placement of QIAsymphony, the leading Sample to Insight workflow automation solution for molecular laboratories worldwide, in Tübingen, Germany. Cenata GmbH is a medically led genetic diagnostic laboratory offering prenatal testing, and repeat customer of... Read more
Venlo, The Netherlands, December 24, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) today announced that it has concluded the previously announced review of potential strategic alternatives, and has determined the execution of its current stand-alone business plan represents the best opportunity to drive future value creation. The Supervisory... Read more
Germantown, Maryland; Hilden, Germany; and Saluggia, Italy, November 27, 2019 –QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated workflow for QuantiFERON-TB Plus (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on DiaSorin’s LIAISON platforms. The U.S. Food and Drug Administration... Read more
Hilden, Germany, and Germantown, Maryland, November 20, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an agreement with LabCorp® (NYSE: LH) to extend their current QIAGEN Clinical Insights (QCI) license with QIAGEN’s Human Gene Mutation Database (HGMD) of human genetic variants, the world’s largest database of inherited disease mutations. This agreement... Read more